Inhibition of chronic graft-vs-host disease with retention of anti-myeloma effects by the proteasome inhibitor bortezomib [1]

Leukemia and Lymphoma

Volumn 48, Issue 5, 2007, Pages 1015-1018

  Todisco, E ^a   Sarina, B ^a   Castagna, L ^a   Mazza, R ^a   Rahal, D ^a   Nozza, A ^a   Santoro, A ^a  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYCLOSPORIN A; FLUDARABINE; IMMUNOGLOBULIN M; LIVER ENZYME; MELPHALAN; METHOTREXATE; STEROID;

ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; BIOPSY TECHNIQUE; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CANCER STAGING; CASE REPORT; CHRONIC GRAFT VERSUS HOST DISEASE; DISEASE COURSE; DISEASE EXACERBATION; DONOR LYMPHOCYTE INFUSION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG WITHDRAWAL; HUMAN; HUMAN TISSUE; IMMUNOMODULATION; LETTER; LIVER BIOPSY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NEUTROPENIA; POLYNEUROPATHY; PRIORITY JOURNAL; RADIATION DOSE; REDUCED INTENSITY CONDITIONING; RETREATMENT; SHORT COURSE THERAPY; THROMBOCYTOPENIA; TREATMENT FAILURE;

ALANINE TRANSAMINASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASES; BORONIC ACIDS; CHRONIC DISEASE; GAMMA-GLUTAMYLTRANSFERASE; GRAFT VS HOST DISEASE; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PROTEASE INHIBITORS; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRAZINES; RECURRENCE; REMISSION INDUCTION;

EID: 34547436160     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190701253843     Document Type: Letter

References (14)

1. Copelan, E. A. (2006) Hematopoietic stem-cell transplantation. N Eng J Med, 354, pp. 1813-1826.
2. Sunwoo, J. B., Chen, Z., Dong, G., Yeh, N., Bancroft, C Crowl and Sausville, E. (2001) Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kB, cell survival, tumor growth and angiogenesis in squamous cell carcinoma. Clin Cancer Res, 7, pp. 1419-1428.
3. Siebenlist, U., Franzoso, G. and Brown, K. (1994) Structure, regulation and function of NF-kB. Ann Rev Biol, 10, pp. 405-455.
4. Blanco, B., Pérez-Simon, J. A., Sánchez-Abarca, L. I., Carvajal-Vergara, X., Mateos, J. and Vidriales, B. (2006) Bortezomib induces selective depletion of alloreactive T lymphocytes and decreases the production of Th1 cytokines. Blood, 107, pp. 3575-3583.
5. Sun, K., Welniak, L. A., Panoskaltsis-Mortari, A., O'Shaughnessy, M. J., Liu, H. and Barao, J. (2004) Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitor bortezomib. Proc Natl Acad Sci USA, 10, pp. 8120-8125.
6. Vodanovic-Jankovic, S., Hari, P., Jacobs, P., Komorowski, R. and Drobyski, W. R. (2006) NF-kappa-B as a target for the prevention of graft-versus-host disease: Comparative efficacy of bortezomib and PS-1145. Blood, 107, pp. 827-834.
7. Kröger, N., Zabelina, T., Ayuk, F., Atanackovic, D., Schieder, H. and Renges, H. (2006) Bortezomib after dose-reduced allogeneic stem cell transplantation for multiple myeloma to enhance or maintain remission status. Exp Hematol, 34, pp. 770-775.
8. Bladé, J., Samson, D., Reece, D., Apperly, J., Bjorkstrand, B. and Gahrton, G. (1998) Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and hematopoietic stem cell tranplantation. Br J Haematol, 102, pp. 1115-1121.
9. Terpos, E., Rezvani, K., Basu, S., Milne, A. E., Rose, P. E. and Scott, G. L. (2005) Plasmacytoma relapses in the absence of systemic progression post-high-dose therapy for multiple myeloma. Eur J Haematol, 75, pp. 376-383.
10. Rosiñol, L., Cibeira, M. T., Uriburu, C., Yantorno, S., Salamero, O. and Bladè, J. (2006) Bortezomib: An effective agent in extramedullary disease in multiple myeloma. Eur J Haematol, 76, pp. 405-408.
11. van de Donk, N WCJ, Kroger, N., Hegenbart, U., Corradini, P., Miguel, J F San and Goldschmidt, H. (2006) Remarkable activity of novel agents bortezomib and thalidomide in patients not responding to donor lymphocyte infusions following nonmyeloablative allogeneic stem cell transplantation in multiple myeloma. Blood, 107, p. 3415.
12. Mohty, M., Attal, M., Marit, G., Bulabois, C. E., Garban, F. and Gratecos, N. (2005) Thalidomide salvage therapy following allogenic stem cell transplantation for multiple myeloma: A retrospective study from the Intergroupe Francophone du Myelome (IFM) and the Societe Française de Greffe de Moelle et Therapie cellulaire (SFGM-TC). Bone Marrow Transplant, 358, pp. 165-169.
13. Koc, S., Leisenring, W., Flowers, M. E., Anaselti, C., Deeg, H. J. and Nash, R. A. (2000) Thalidomide for treatment of patients with chronic graft-versus-host disease. Blood, 96, pp. 3995-3996.
14. Rosiñol, L., Cibeira, M. T., Bladè, J., Esteve, J., Aymerich, M. and Rozman, M. (2004) Extramedullary multiple myeloma escapes the effect of thalidomide. Hematologica, 89, pp. 832-836.